Related Experiment Video
Updated: Feb 11, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[Research and Applications Progress of Lenalidomide in Relapsed / Refractory Blood System Diseases -Review]
Wen-Jing Fan1, Zhi-Qiao Fan2, Tao Wu2
1Center of Hematologic Diseases of Chinese PLA, Lanzhou Military Command General Hospital, Lanzhou 730050, Gansu Province, China; The Second Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China.
Abstract:
Lenalidomide, a novel immunomodulatory agent, is a kind of thalidomide derivatives, which shows a good efficacy and safety for hematological system diseases. This review is aimed to evaluate the efficacy and safety of lenalidomide in treatment of patients with multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, classical Hodgkin's lymphoma and POEMS syndrome at their replased or refractory state. At the same time, this review focuses on the newest clinical research and the latest application progress of lenalidomide for relapsed or refractory hematological system diseases.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Applications of Integration to Find Blood Flow
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

